Orexigen Therapeutics Inc. (OREX) Trading 6.2% Higher
Orexigen Therapeutics Inc. (NASDAQ:OREX)’s share price traded up 6.2% during trading on Monday . The company traded as high as $4.52 and last traded at $4.44, with a volume of 110,780 shares traded. The stock had previously closed at $4.18.
Separately, Zacks Investment Research lowered shares of Orexigen Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, August 9th. One research analyst has rated the stock with a sell rating and eight have given a hold rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $2.04.
The firm’s 50 day moving average is $3.88 and its 200 day moving average is $6.69. The stock’s market capitalization is $63.30 million.
Orexigen Therapeutics (NASDAQ:OREX) last posted its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.73) earnings per share for the quarter, missing the consensus estimate of ($1.47) by $0.26. During the same quarter last year, the firm earned ($0.18) EPS. The business had revenue of $7.79 million for the quarter, compared to the consensus estimate of $6.88 million. Orexigen Therapeutics’s revenue was up 50.0% compared to the same quarter last year. Analysts anticipate that Orexigen Therapeutics Inc. will post ($6.08) EPS for the current year.
Orexigen Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company’s product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.